Adaptive, personalized closed-loop therapy for Parkinson's disease: biochemical, neurophysiological, and wearable sensing systems

Expert Rev Neurother. 2021 Dec;21(12):1371-1388. doi: 10.1080/14737175.2021.2000392. Epub 2021 Nov 17.ABSTRACTINTRODUCTION: Motor complication management is one of the main unmet needs in Parkinson's disease patients.AREAS COVERED: Among the most promising emerging approaches for handling motor complications in Parkinson's disease, adaptive deep brain stimulation strategies operating in closed-loop have emerged as pivotal to deliver sustained, near-to-physiological inputs to dysfunctional basal ganglia-cortical circuits over time. Existing sensing systems that can provide feedback signals to close the loop include biochemical-, neurophysiological- or wearable-sensors. Biochemical sensing allows to directly monitor the pharmacokinetic and pharmacodynamic of antiparkinsonian drugs and metabolites. Neurophysiological sensing relies on neurotechnologies to sense cortical or subcortical brain activity and extract real-time correlates of symptom intensity or symptom control during DBS. A more direct representation of the symptom state, particularly the phenomenological differentiation and quantification of motor symptoms, can be realized via wearable sensor technology.EXPERT OPINION: Biochemical, neurophysiologic, and wearable-based biomarkers are promising technological tools that either individually or in combination could guide adaptive therapy for Parkinson's disease motor symptoms in the future.PMID:34736368 | DOI:10.1080/14737175.2021.2000392
Source: Expert Review of Neurotherapeutics - Category: Neurology Authors: Source Type: research